Categories AlphaGraphs, Analysis, Technology
Salesforce stock slumps on weak outlook despite upbeat Q4 earnings
Stock-trend disruptor Salesforce (CRM) posted its fourth-quarter earnings on March 4, Monday, after the closing bell.
Total quarterly revenue jumped 26% to $3.60 billion. Earnings was 46 cents per diluted share, while non-GAAP diluted earnings was $0.70 a share.
While many are of the opinion that the stock is overvalued, the market touted Salesforce to earn 55 cents a share on revenue of about $3.5 billion. This is almost 25% higher top-line than a year ago.
Unearned revenue on the balance sheet as of January 31, 2019 was $8.56 billion, up 22% year-over-year. For the year, revenue grew 26% to $13.28 billion, generating earnings of $1.43 per diluted share.
“This is just the beginning, which is why we’re now targeting $26 to $28 billion in revenue by FY23 – organically doubling our revenue again in the next four years,” said Salesforce co-CEO Keith Block.
LOOKING FORWARD
In the upcoming first-quarter of fiscal 2020, Salesforce sees quarterly revenue grow about 22% to hit $3.67-3.68 billion, generating GAAP EPS of $0.10-0.11 and Non-GAAP EPS of $0.60-0.61.
For the fiscal year 2020, the company touts revenue to jump 20-21% and reach between $15.95 and $16.05 billion. Salesforce expects to earn 66 to 68 cents per share on a GAAP basis, and $2.74-2.76 per adjusted share.
Despite top-line and bottom-line results beating the Street consensus, the stock fell in after-market trade as investors did not take kindly to the tepid outlook.
Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings
After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform
What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
Comments